HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105
Benzinga Newsdesk 1 year ago
NewsPrice TargetSmall CapAnalyst Ratings
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $70 to $105.
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $70 to $105.